This paper is in the following e-collection/theme issue:

Connected Health Conference Abstracts (2019) (34)

Published on in Vol 5, No 1 (2019): CHC19

A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

Authors of this article:

Guilherme Safioti1 ;   Lena Granovsky2 ;   Thomas Li3 ;   Michael Reich2 ;   Shahar Cohen4 ;   Yonatan Hadar4 ;   Roy Pleasants5 ;   Henry Chrystyn6 ;   Tanisha Hill3 ;   Michael DePietro3
Article Authors Cited by (5) Tweetations Metrics

Journals

  1. Ilowite J, Lisker G, Greenberg H. Digital Health Technology and Telemedicine-Based Hospital and Home Programs in Pulmonary Medicine During the COVID-19 Pandemic. American Journal of Therapeutics 2021;28(2):e217 View
  2. Furman E, Khuzina E. Age-related features of the choice of inhalers in chilren and adolescents with bronchial asthma and other respiratory diseases. Meditsinskiy sovet = Medical Council 2024;(9):92 View
  3. Xiroudaki S, Schoubben A, Giovagnoli S, Rekkas D. Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives. Pharmaceutics 2021;13(9):1455 View
  4. Mysovskikh I, Legg M, Demidenko S. Flowrate Sensing and Measurement in Portable Smart Inhalers. Sensors 2024;24(21):6848 View
  5. Cokorudy B, Harrison J, Chan A. Digital markers of asthma exacerbations: a systematic review. ERJ Open Research 2024;10(6):00014-2024 View